Navigation Links
Study Published in Otology & Neurotology Shows Benefits of Cochlear Implant Sound Processor with Dual-Microphone Technology
Date:11/5/2012

CENTENNIAL, Colo., Nov. 5, 2012 /PRNewswire/ --  Cochlear Americas, the world's leading implantable hearing solutions company, announced today the results of a new study published in Otology & Neurotology, which demonstrates the benefit of the dual-microphone technology in the Cochlear Nucleus 5 CP810 Sound Processor.  The study illustrates how the Nucleus 5 sound processor provides significantly better speech recognition in quiet and in noise when compared with the performance of the Cochlear Nucleus® Freedom™ processor. 

"Cochlear implants are highly successful devices for many adults who have severe to profound hearing loss; however, most recipients continue to experience difficulty understanding speech in the presence of competing noise," said Jace Wolfe , Ph.D., CCC-A, Hearts for Hearing, Oklahoma City, lead study investigator. "Results from this study indicate that the Nucleus 5 sound processor provided a significant improvement in speech recognition relative to the performance with the previous generation sound processor."

The Nucleus 5 sound processor contains two microphones, which are precisely calibrated and phase matched to +/- 1 dB tolerance to ensure accuracy and consistency.  With two microphones the Nucleus 5 provides a directional mode called "SmartSound® zoom" technology, which significantly lessens competing background noises, as well as enhancements in the signal processing chip to enhance speech recognition in quiet and noise.

"This study demonstrates our commitment to continually improving the experience of our recipients," said Christine Menapace, MA, CCC-A, Vice President of Clinical, Training and Education at Cochlear. "Every new generation of the Nucleus Sound Processor has been backwards-compatible, enabling our cochlear implant users to upgrade to the latest technological improvements, such as the dual-microphone 'SmartSound® zoom' technology."

To hear the benefits of the dual microphones on the Nucleus 5 sound processor first-hand, visit http://www.cochlearamericas.com/performance or download the "Dual Mic Zoom Technology from Cochlear" iPad app for free from iTunes®.

About the Study
This study – "Benefit of a Commercially Available Cochlear Implant Processor With Dual-Microphone Beamforming: A Multi-Center Study" – was conducted across four cochlear implant clinics in the United States. Thirty-five adult Nucleus recipients were upgraded to the Nucleus 5 Sound Processor and speech recognition was assessed with CNC monosyllabic words in quiet and sentences in noise from the BKB-SIN (Bamford-Kowal-Bench Sentences in Noise) test. The primary objective of the study was to compare speech recognition in quiet and in noise for the Nucleus Freedom and Nucleus 5 CP810 Sound Processors set to the manufacturer's default user programs for quiet and noisy environments.

About Cochlear Implants
Cochlear implants are a proven medical option for infants as young as 12 months old with profound hearing loss in both ears, children aged two and older with severe-to-profound hearing loss, and adults with moderate-to-profound hearing loss in both ears. They are electronic devices, which bypass damaged hair cells in the inner ear, or cochlea, and stimulate the hearing nerve directly.

About Cochlear
Cochlear is the world leader in advanced hearing technologies. Since launching the first multichannel cochlear implant system 30 years ago, Cochlear Limited and its U.S. headquarters have brought the miracle of sound to more than 250,000 people with hearing loss across the globe. For more information about Cochlear Americas products, please visit www.cochlearamericas.com.


'/>"/>
SOURCE Cochlear Americas
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):